Penumbra, Inc.
private/Boston Scientific CorporationBSXBoston Scientific to acquire Penumbra in $374/share mixed consideration deal
Deal value
—
mixed
Per-share offer
—
Premium
—
Days to close
—
Term fee
—
No structured deal economics extracted yet. Re-run the scanner or fall back to the source filing below.
Announced
Apr 24, 2026
Preliminary Proxy
—
Definitive Proxy
—
Record date
—
Shareholder vote
—
Expected close
—
No regulatory or closing-conditions data extracted yet. The merger agreement Exhibit 10.1 contains this in the “Conditions to Closing” and “Regulatory Approvals” articles.
No closing-condition data extracted.
No competing-bidder, activist, or dissident-proxy signals in the database for this target.
Acquirer side· Boston Scientific Corporation
Legal
Allen Overy Shearman Sterling US LLP
- · Clare O'Brien
- · Derrick Lott
- · Richard Alsop
“Copies to: Clare O'Brien, Esq.Derrick Lott, Esq.Richard Alsop, Esq.Allen Overy Shearman Sterling US LLP 599 Lexington Avenue New York, New York 10022 (212) 848-4000”
- · Alan Denenburg
- · Michael Diz
“Alan Denenburg, Esq.Michael Diz, Esq.Davis Polk & Wardwell LLP 900 Middlefield Road Redwood City, CA 94063 (650) 752-2000”
Target side· Penumbra, Inc.
None on record
| Firm | Role | Side | Deals in DB | |
|---|---|---|---|---|
| Davis Polk & Wardwell LLP | Legal | Acquirer | 3 | View deals → |
| Allen Overy Shearman Sterling US LLP | Legal | Acquirer | 1 | View deals → |
- Apr 24, 2026this filing
Boston Scientific to acquire Penumbra in $374/share mixed consideration deal
- Apr 24, 2026
Boston Scientific to acquire Penumbra for $374/share in cash and stock
| Date | Form | Section | Headline | Status |
|---|---|---|---|---|
| Apr 24, 2026 | — | definitive | Boston Scientific to acquire Penumbra for $374/share in cash and stock | vote_scheduled |
Boston Scientific Corporation agreed to acquire Penumbra, Inc. in an all-cash and stock transaction pursuant to an Agreement and Plan of Merger dated January 14, 2026. The merger consideration is $374.00 per share, payable at the election of shareholders as either $374.00 in cash or 3.8721 Boston Scientific shares (subject to proration with 73.26% cash and 26.74% stock), with the transaction expected to close following shareholder approval. The combination aims to leverage Boston Scientific's global reach and Penumbra's advanced technology to expand patient access to innovative medical devices.